Stockscreener 앱 받기
13.91
1.83%
0.25
시장 영업 전:
14.24
0.33
+2.37%
전일 마감가:
$13.66
열려 있는:
$13.75
하루 거래량:
846.06K
Relative Volume:
2.91
시가총액:
$700.53M
수익:
$62.02M
순이익/손실:
$-45.65M
주가수익비율:
-15.12
EPS:
-0.92
순현금흐름:
$-9.60M
1주 성능:
+5.78%
1개월 성능:
+23.86%
6개월 성능:
+49.33%
1년 성능:
+73.66%
1일 변동 폭
$13.65
$13.93
1주일 범위
$13.18
$14.30
52주 변동 폭
$7.88
$14.30
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
13.91 | 685.42M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Theravance Biopharma reaches patent settlement with Cipla on YUPELRI inhalation - Investing.com
Does Theravance Biopharma Inc. qualify in momentum factor screeningJuly 2025 Rallies & Verified Entry Point Detection - Newser
Using data models to predict Theravance Biopharma Inc. stock movementJuly 2025 Technicals & Smart Allocation Stock Tips - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedWeekly Market Outlook & High Accuracy Buy Signal Tips - Newser
What’s the recovery path for long term holders of Theravance Biopharma Inc.2025 Support & Resistance & Low Risk Profit Maximizing Plans - Newser
Best data tools to analyze Theravance Biopharma Inc. stock2025 Volatility Report & Proven Capital Preservation Tips - Newser
Is Theravance Biopharma Inc. a momentum stock2025 Winners & Losers & Daily Technical Stock Forecast Reports - classian.co.kr
What earnings revisions data tells us about Theravance Biopharma Inc.2025 Volatility Report & AI Powered Buy/Sell Recommendations - Newser
Using Ichimoku Cloud for Theravance Biopharma Inc. technicals2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Theravance Biopharma Inc. stock undervalued right now2025 Market WrapUp & Low Risk Entry Point Tips - classian.co.kr
Tools to monitor Theravance Biopharma Inc. recovery probabilityJuly 2025 Action & Daily Profit Focused Stock Screening - Newser
How Theravance Biopharma Inc. stock performs during market volatilityJuly 2025 Setups & High Accuracy Investment Signals - Newser
Is Theravance Biopharma Inc. still worth holding after the dip2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Candlestick Signal Suggests Reversal in Theravance Biopharma Inc.2025 Volume Leaders & Real-Time Volume Analysis Alerts - metal.it
Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen - Defense World
What institutional flow reveals about Theravance Biopharma Inc.Weekly Investment Summary & Consistent Income Trade Ideas - Newser
Real time social sentiment graph for Theravance Biopharma Inc.2025 Top Decliners & AI Driven Price Predictions - Newser
Candlestick Reversal Detected on Theravance Biopharma Inc.’s ChartJuly 2025 Fed Impact & Reliable Volume Spike Alerts - metal.it
What makes Theravance Biopharma Inc. stock price move sharplyJuly 2025 Snapshot & Short-Term Trading Opportunity Alerts - thegnnews.com
H.C. Wainwright Maintains Buy Rating for Theravance Biopharma with $15 Price Target - AInvest
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
H.C. Wainwright Sticks to Their Buy Rating for Theravance Biopharma (TBPH) - The Globe and Mail
The 11% Return This Week Takes Theravance Biopharma's (NASDAQ:TBPH) Shareholders One-year Gains to 51% - 富途牛牛
Theravance Biopharma Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by XTX Topco Ltd - Defense World
Theravance Biopharma’s Earnings Call Highlights Strategic Gains - TipRanks
Theravance Biopharma, Inc. SEC 10-Q Report - TradingView
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Theravance Biopharma stock price target raised to $13 by Leerink Partners - Investing.com South Africa
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma stock price target raised to $13 by Leerink Partners By Investing.com - Investing.com Nigeria
Theravance Biopharma shares fall 1.85% premarket despite strong Q2 earnings and positive operational updates. - AInvest
Theravance Biopharma Q2 2025 Earnings Call Transcript - MarketBeat
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... - Yahoo Finance
Theravance Sales Jump 83 Percent - AOL.com
Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High Following Strong Earnings - Defense World
Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout - MSN
Technical signs of recovery in Theravance Biopharma Inc. [Analyst Upgrade]Free Safe Entry Momentum Stock Tips - Newser
Theravance Biopharma Reports Strong Q2 2025 Results - TipRanks
Theravance Biopharma: Hold Rating Amid Temporary Revenue Gains and Pipeline Uncertainty - TipRanks
Theravance Biopharma Reports Q2 2025 Results with 83.2% Revenue Growth, Exceeding Analyst Expectations - AInvest
Theravance Bio: Q2 Earnings Snapshot - Big Rapids Pioneer
Theravance Sales Jump 83 Percent - The Motley Fool
Theravance Biopharma (TBPH): A High-Conviction Play on Rare Disease Innovation and Durable Cash Flow - AInvest
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics - AInvest
Theravance Biopharma Expects $150M in Milestone Payments as CYPRESS Trial Approaches Pivotal Data Readout - AInvest
Theravance Biopharma's Q2 Surge: A Case Study in Biotech Resilience and Strategic Precision - AInvest
Earnings call transcript: Theravance Biopharma Q2 2025 earnings beat expectations - Investing.com
Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples - Investing.com Canada
Theravance Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):